ADVFN - Advanced Financial Network.
HOME» NASDAQ » T » TEVA Stock Price » TEVA Stock News

Teva Pharmaceutical Share News

 Teva Pharmaceutical Industries Limited (mm) Stock Price
TEVA Stock Price
 Teva Pharmaceutical Industries Limited (mm) Stock Chart
TEVA Stock Chart
 Teva Pharmaceutical Industries Limited (mm) Stock News
TEVA Stock News
 Teva Pharmaceutical Industries Limited (mm) Company Information
TEVA Company Information
 Teva Pharmaceutical Industries Limited (mm) Stock Trades
TEVA Stock Trades

US Court Rules For AstraZeneca's Seroquel XR Patent

DOW JONES NEWSWIRES A U.S. district court found the formulation patent for AstraZeneca PLC's (AZN, AZN.LN) top-selling antipsychotic drug Seroquel XR was valid, the pharmaceutical company said Thursday, offering it ammunition in its fight against generic versions of the drug. The U.S. District Court for New Jersey also found Par Pharmaceutical Cos.'s (PRX) Anchen Pharmaceuticals, Osmotica Pharmaceutical Corp., Torrent Pharmaceuticals Ltd. (500420.BY) and Mylan Pharmaceuticals Inc. had infringed the drug's extended-release formulation patent, which expires in 2017, AstraZeneca said. The ruling comes after the U.K.'s second-biggest drug company failed this month to prevent the U.S. Food and Drug Administration from giving final marketing approval to generic forms of Seroquel. A federal judge Friday refused to grant AstraZeneca an injunction against the FDA, ruling that the company had failed to make a clear case that it was entitled to one. AstraZeneca faces one of the highest exposures to drug-patent expirations within the pharmaceuticals sector. Seroquel, AstraZeneca's second best-selling product, generated $5.83 billion in revenue last year for the company and is the first of its best-selling drugs to lose U.S. patent protection. A U.K. court ruled against AstraZeneca's formulation patent following challenges from companies such as Teva Pharmaceutical Industries Ltd. (TEVA, TEVA.TV). AstraZeneca's American depositary shares Thursday closed at $44.50 and were inactive after-hours. -By Drew FitzGerald, Dow Jones Newswires; 212-416-2909; Andrew.FitzGerald@dowjones.com

Stock News for Teva Pharmaceutical (TEVA)
DateTimeHeadline
05/29/201217:52:10FDA Warns About Fake Version Of Teva's ADHD Drug Adderall
05/29/201217:47:50Pronova Wins Heart-Drug Patent Case Against Teva, Par Pharma
05/24/201209:38:21Teva Pharma Reduces 2012 Guidance On Lower Generics View
05/17/201215:17:50FDA Approves Generic Versions Of Blood Thinning Drug Plavix
05/09/201207:17:36Teva Profit Surges In First Quarter On Branded, Generic Drug...
04/30/201203:04:09Consort Gets FDA Approval For Its Integrated Dose Counter
04/26/201210:12:05Mylan 1Q Profit Rises 24%; EpiPen Settlement Reached With Teva
04/24/201208:26:02Watson, Actavis To Unveil EUR4.5 Billion Merger Deal Wednesday
04/05/201213:24:34Mylan Seeks To Overturn FDA's Provigil Decision
04/03/201202:15:49Glenmark Unit Gets US OK To Sell Copy Of Contraceptive Drug
03/29/201218:40:14US Court Rules For AstraZeneca's Seroquel XR Patent
03/29/201206:32:55Teva Revises Pricing On Euro 7-year Bond To Swaps +1.05 Area
03/28/201217:53:08Myriad Genetics Enters Testing Agreement With Teva Subsidiary
03/26/201204:57:02AstraZeneca Loses Bid To Delay Generics Of Seroquel In US Market
03/21/201212:59:07Drug Maker Watson To Buy Actavis For About EUR4.5 Billion - Source
03/21/201210:55:24Teva Pharmaceutical To Switch Listing To NYSE In May
03/14/201214:58:34Teva Receives FDA Approval For Generic Lexapro For Adults
03/08/201210:10:11Teva: FDA Approves Dose Counter For ProAir HFA Asthma Drug
02/21/201207:50:17Mylan 4Q Net Soars On Year-Earlier Items, Improved Margins
02/15/201212:54:13FDA Approves BioSante Gel for Male Low Testosterone; Shares Up

Teva Pharmaceutical and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad